News

Under the deal, Fresenius Kabi will pay $34.00 per Akorn share, in addition to assuming around $450m of debt. Akorn is engaged in the development, manufacturing and marketing

The marketing authorization of the gene therapy was approved in 2012 for the treatment of patients with familial lipoprotein lipase deficiency (LPLD). According to the Dutch gene therapy

NGM282, which is a non-tumorigenic, engineered variant of the human hormone FGF19, demonstrated a significant reduction in liver fat content and improvement of biomarkers associated with the resolution

Mark Levick, MD PhD, Global Head of Development, Biopharmaceuticals, Sandoz, said: "We are proud to help patients in Europe with blood cancers and immunological diseases by improving their

CCP-07, which is being developed by Tris Pharma, is a cough-cold formulation being developed for the US prescription cough-cold market. The FDA issued complete response letter (CRL) for CCP-07, which

The trial, dubbed EXPEDITION-1, featured patients having chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A), and subjected to

H3 and Foundation Medicine will continue to build upon the progress the two companies have made during the collaboration. The companies will collaborate to interrogate the FoundationCORE dataset,

Immune and Pint target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American

Upsher-Smith’s portfolio includes around 30 pharmaceutical products, specifically intended for oral solid preparations. The acquired business will enables Sawai to develop a US business, in addition to combining R&D